TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20066671

Group type: EXPERIMENTAL
Intervention: Escitalopram treatment for 5 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment) for 1 week
Number of subjects: 30
Study: 17578661

Group type: EXPERIMENTAL
Intervention: Consistent condom use
Number of subjects: 0
Study: 15881486

Group type: EXPERIMENTAL
Intervention: etoricoxib 120 mg
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: oxycodone/acetaminophen 10 mg/650 mg
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: codeine/acetaminophen 60 mg/600 mg
Number of subjects: 302

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 302
Study: 12361064

Group type: EXPERIMENTAL
Intervention: Miniplate osteosynthesis according to Champy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 10449889

Group type: EXPERIMENTAL
Intervention: Valsartan (Diovan(R))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0
Study: 7590440

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study: 2183939

Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sucralfate 2 gm twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 377081

Group type: EXPERIMENTAL
Intervention: Ticrynafen 500 mg once daily
Number of subjects: 240

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 or 100 mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Ticrynafen and Hydrochlorothiazide
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Ticrynafen
Number of subjects: 240
Study: 31601571

Group type: EXPERIMENTAL
Intervention: Rojiroti microfinance intervention
Number of subjects: 2469
Study: 28973149

Group type: EXPERIMENTAL
Intervention: stAPP smartphone-based intervention (smartphone, smartphone app, and corresponding motion sensor)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 58
Study: 27631594

Group type: EXPERIMENTAL
Intervention: Basket catheter
Number of subjects: 184

Group type: COMPARATOR
Intervention: Balloon catheter
Number of subjects: 184
Study: 28059433

Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Naloxegol 12.5 mg
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Naloxegol (both doses)
Number of subjects: 302
Study: 25286684

Group type: EXPERIMENTAL
Intervention: Reinforcing Qi and Activating Blood treatment (Yu‐Ping‐Feng capsules and Fu‐Fang‐Dan‐Shen tablets for 3 months)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Reinforcing Qi and Activating Blood treatment
Number of subjects: 50
Study: 22326816

Group type: EXPERIMENTAL
Intervention: Case studies combined with concept maps (CSCM)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Case studies alone (CS)
Number of subjects: 67
Study: 19393842

Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6%
Number of subjects: 269

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Both groups (Besifloxacin and Vehicle)
Number of subjects: 269
Study: 17202548

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (N=79)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Waiting list comparison group (N=64)
Number of subjects: 143
Study: 16135469

Group type: EXPERIMENTAL
Intervention: Peer-modeling videotape (VID)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Standard print material, videotape, two sessions with a trained cancer educator, and informational workbook (EDU)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Standard National Cancer Institute print material (CTL)
Number of subjects: 558
Study: 11975150

Group type: EXPERIMENTAL
Intervention: High control condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low control condition
Number of subjects: 40
Study: 9299914

Group type: EXPERIMENTAL
Intervention: Principal Component Analysis (PCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Möcks's Topographic Component Model (TCM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulations using seven imperfect rotations
Number of subjects: 0
Study: 8196410

Group type: EXPERIMENTAL
Intervention: Needling extrachannel points
Number of subjects: 20

Group type: COMPARATOR
Intervention: Amitriptyline (control)
Number of subjects: 20
Study: 3595695

Group type: EXPERIMENTAL
Intervention: Amiodarone (3 X 400 mg daily for 3 days) plus Methimazole (3 X 20 mg daily for 10 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo plus Methimazole (3 X 20 mg daily for 10 days)
Number of subjects: 10
Study: 31355873

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy with medical management (EVT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Medical management only (MM)
Number of subjects: 105
Study: 29489494

Group type: EXPERIMENTAL
Intervention: St John's wort extract LI160
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 26864951

Group type: EXPERIMENTAL
Intervention: Bioresorbable polymer sirolimus‐eluting stent (BP‐SES)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Permanent polymer everolimus‐eluting stent (PP‐EES)
Number of subjects: 182
Study: 24757229

Group type: EXPERIMENTAL
Intervention: Automated predictive low glucose pump suspension system
Number of subjects: 45

Group type: COMPARATOR
Intervention: No pump suspension (control)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control nights (no intervention)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pump suspension exceeding 2 hours
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Automated pump suspension system
Number of subjects: 45
Study: 22891219

Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 742

Group type: COMPARATOR
Intervention: Low-protein diet
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Diet interventions (four diets differing in fat, protein, and carbohydrate proportions)
Number of subjects: 742
Study: 20435275

Group type: EXPERIMENTAL
Intervention: Female-oriented intervention group
Number of subjects: 808

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 808
Study: 18585514

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 9971

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 9971

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 9971

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 9971

Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 9971
Study: 15854139

Group type: EXPERIMENTAL
Intervention: 2 g intravenous ascorbic acid
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 15328062

Group type: EXPERIMENTAL
Intervention: Recombinant human GH infusion (10 microg/kg, 6‐min square wave pulse)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 9
Study: 10752814

Group type: EXPERIMENTAL
Intervention: Physiotherapy (breathing exercises, huffing, and coughing) plus incentive spirometry
Number of subjects: 67

Group type: COMPARATOR
Intervention: Physiotherapy (breathing exercises, huffing, and coughing) alone
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Physiotherapy plus incentive spirometry
Number of subjects: 67

Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 67
Study: 9496559

Group type: EXPERIMENTAL
Intervention: Octreotide (50 mcg)
Number of subjects: 9
Study: 8471373

Group type: EXPERIMENTAL
Intervention: Preoperative indomethacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative indomethacin
Number of subjects: 0
Study: 4031109

Group type: EXPERIMENTAL
Intervention: Indenolol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 18
Study: 3064919

Group type: EXPERIMENTAL
Intervention: Nimodipine 40 mg three times a day
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 31808598

Group type: EXPERIMENTAL
Intervention: Oral bambuterol hydrochloride (10 mg, once daily, for 3 days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 51
Study: 30242962

Group type: EXPERIMENTAL
Intervention: NYX-2925 (50-1200 mg single-ascending dose and 150-900 mg multiple-ascending dose)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: NYX-2925
Number of subjects: 84
Study: 31966779

Group type: EXPERIMENTAL
Intervention: Autolysis debridement and mechanical debridement
Number of subjects: 22
Study: 26580240

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg three times a day for 3 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 24007570

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Tacrolimus (Tac)
Number of subjects: 200
Study: 21504952

Group type: EXPERIMENTAL
Intervention: Plantar perception training using a hardness discrimination task
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (simply remaining standing on foam rubber)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Plantar perception training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 19082699

Group type: EXPERIMENTAL
Intervention: ACE-inhibitor perindopril
Number of subjects: 12218

Group type: EXPERIMENTAL
Intervention: Genetic factors
Number of subjects: 12218

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic profiling
Number of subjects: 12218
Study: 16390284

Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy (IRT)
Number of subjects: 0
Study: 14734956

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 11561868

Group type: EXPERIMENTAL
Intervention: Oral proteolytic enzyme preparation (enzyme tablets t.i.d. starting 3 days prior to radiation therapy and continuing up to 5 days after completion)
Number of subjects: 100
Study: 9301350

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (400 micrograms/day)
Number of subjects: 23
Study: 8421038

Group type: EXPERIMENTAL
Intervention: Ultrasound control for closed femoral nailing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional methods with an image intensifier
Number of subjects: 30
Study: 3717115

Group type: EXPERIMENTAL
Intervention: Sodium benzoate and sodium phenylacetate
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional therapy (lactulose or neomycin)
Number of subjects: 8
Study: 29570907

Group type: EXPERIMENTAL
Intervention: Probiotic intervention with Lactobacilli reuteri (DSM 17938 and ATCC PTA 5289)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 28061543

Group type: EXPERIMENTAL
Intervention: GTDS (transdermal granisetron patch, 7 days)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Oral granisetron (2 mg/day, ≥2 days)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: GTDS and Oral granisetron
Number of subjects: 313
Study: 25499944

Group type: EXPERIMENTAL
Intervention: 220.5 mg of cis-palmitoleic acid once per day for 30 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (1000 mg of medium chain triglycerides) once per day for 30 days
Number of subjects: 60
Study: 23841969

Group type: EXPERIMENTAL
Intervention: Active video gaming (50-60 minutes/day, 4 days/week, for 5 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal activity (control group)
Number of subjects: 30
Study: 20134177

Group type: EXPERIMENTAL
Intervention: Orbotron training
Number of subjects: 15

Group type: COMPARATOR
Intervention: Weight training
Number of subjects: 15

Group type: COMPARATOR
Intervention: Running training
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All training types
Number of subjects: 15
Study: 18023435

Group type: EXPERIMENTAL
Intervention: Testosterone therapy for low sexual desire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endogenous androgen levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher endogenous serum androgen levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Androgenic hormonal replacement regimens
Number of subjects: 0
Study: 15722593

Group type: EXPERIMENTAL
Intervention: Group-based behavioral education (OPSMC)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Low T-score
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: None (general findings)
Number of subjects: 470
Study: 12878918

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combination of Naltrexone and Acamprosate
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Medical Management (MM)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combined Behavioral Intervention (CBI)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: CBI alone without pills
Number of subjects: 108
Study: 10479196

Group type: EXPERIMENTAL
Intervention: Endurance training (3 d/wk for 20 weeks, starting at 55% VO(2)max for 30 min/session, increasing to 75% VO(2)max for 50 min/session)
Number of subjects: 557
Study: 8952583

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg oral dose)
Number of subjects: 6
Study: 1784658

Group type: EXPERIMENTAL
Intervention: Complete stem
Number of subjects: 166

Group type: COMPARATOR
Intervention: Incomplete stem
Number of subjects: 166
Study: 7259838

Group type: EXPERIMENTAL
Intervention: Single alkylating agent chemotherapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cyclophosphamide, vincristine, and prednisone (CVP)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Fractionated whole body irradiation followed by low dose involved field irradiation
Number of subjects: 51

Group type: COMPARATOR
Intervention: All treatment options
Number of subjects: 51
Study: 31973700

Group type: EXPERIMENTAL
Intervention: Levobupivacaine/morphine (LM)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Levobupivacaine (L)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 150
Study: 29785399

Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT) at 30 minutes post-breakfast (EX30)
Number of subjects: 26

Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT) at 60 minutes post-breakfast (EX60)
Number of subjects: 26

Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT) at 90 minutes post-breakfast (EX90)
Number of subjects: 26
Study: 27457568

Group type: EXPERIMENTAL
Intervention: Music therapy intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 60
Study: 24116959

Group type: EXPERIMENTAL
Intervention: Ustekinumab with immediate methotrexate withdrawal (arm 1)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Ustekinumab with 4-week gradual methotrexate withdrawal (arm 2)
Number of subjects: 489
Study: 22142548

Group type: EXPERIMENTAL
Intervention: Post-paracentesis intravenous nutritional support with a balanced oral diet and a late-evening protein snack (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral nutritional protocol without parenteral support (Group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low-sodium or sodium-free diet (Group C)
Number of subjects: 120
Study: 20350360

Group type: EXPERIMENTAL
Intervention: Olfactory ensheathing cells (OECs) transplantation, injected into the bilateral corona radiata in the frontal lobes
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no OECs transplantation)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Olfactory ensheathing cells (OECs) transplantation
Number of subjects: 33
Study: 17208951

Group type: EXPERIMENTAL
Intervention: DHEA therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHEA therapy in women with adrenal insufficiency
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15621325

Group type: EXPERIMENTAL
Intervention: Walking in water at a self-determined pace
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Walking in water with additional loads (8 kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Walking on land (slow walking)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Walking on land (fast walking)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Walking in water (fast walking)
Number of subjects: 16
Study: 12140146

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Palliative care
Number of subjects: 116
Study: 9927843

Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolytic treatment
Number of subjects: 0
Study: 8601041

Group type: EXPERIMENTAL
Intervention: Combination of mannitol (50 g) and albumin (75 g) in the pump prime
Number of subjects: 103

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 103
Study: 2632375

Group type: EXPERIMENTAL
Intervention: Antianxiety drug
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Antidepressant
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: COMPARATOR
Intervention: Psychotherapy
Number of subjects: 48
Study: 4925514

Group type: EXPERIMENTAL
Intervention: Antimalarials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31980899

Group type: EXPERIMENTAL
Intervention: Body-oriented resilience therapy (BEATVIC)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Befriending (Control)
Number of subjects: 27
Study: 30476940

Group type: EXPERIMENTAL
Intervention: Prophylactic intraperitoneal mesh implantation
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard abdominal closure
Number of subjects: 150
Study: 27301484

Group type: EXPERIMENTAL
Intervention: Multistrategy childcare-based intervention including staff training, resources, audit and feedback, ongoing support, and securing executive support.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care control group.
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Multistrategy childcare-based intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 58
Study: 24602409

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 22821414

Group type: EXPERIMENTAL
Intervention: Percutaneous distal metatarsal osteotomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Distal chevron osteotomy
Number of subjects: 64
Study: 20537501

Group type: EXPERIMENTAL
Intervention: Glutamine group (l‐glutamine 0.4g/[kg d])
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glutamine group
Number of subjects: 30
Study: 18544001

Group type: EXPERIMENTAL
Intervention: Oral voriconazole (200 mg single dose)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intravenous voriconazole solubilized with SBECD (6 mg/kg twice daily on day 1, then 3 mg/kg twice daily from days 2-6, followed by 3 mg/kg on day 7)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intravenous voriconazole solubilized with SBECD
Number of subjects: 41
Study: 15752161

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) infusion followed by platelet concentrates (PCs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12625491

Group type: EXPERIMENTAL
Intervention: Coronary Angiography (CA)
Number of subjects: 2493

Group type: COMPARATOR
Intervention: No Coronary Angiography (No CA)
Number of subjects: 2493
Study: 9758088

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 14400

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 14400
Study: 1929272

Group type: EXPERIMENTAL
Intervention: Norfloxacin 200 mg daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Nitrofurantoin 50 mg daily
Number of subjects: 102
Study: 6800439

Group type: EXPERIMENTAL
Intervention: Intranasal insulin with sodium glycocholate
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Intravenous insulin
Number of subjects: 7
Study: 30977081

Group type: EXPERIMENTAL
Intervention: Computerized dynamic posturography (CDP) training, optokinetic stimulus, or exercise at home
Number of subjects: 57
Study: 31530577

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study: 28591282

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (IVTA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 35
Study: 27062270

Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 24442886

Group type: EXPERIMENTAL
Intervention: 5 mg intravenous zoledronate
Number of subjects: 100
Study: 22435747

Group type: EXPERIMENTAL
Intervention: G+P (Granulocyte colony-stimulating factor with plerixafor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: G-CSF (Granulocyte colony-stimulating factor)
Number of subjects: 0
Study: 18981719

Group type: EXPERIMENTAL
Intervention: Epoetin beta 10,000 IU thrice weekly and oral iron starting 10-15 days before treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard supportive care (no epoetin beta)
Number of subjects: 120
Study: 17670860

Group type: EXPERIMENTAL
Intervention: 35 days ULLS+RE
Number of subjects: 48

Group type: COMPARATOR
Intervention: 35 days ULLS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 90 days BR+RE
Number of subjects: 48

Group type: COMPARATOR
Intervention: 90 days BR
Number of subjects: 48
Study: 15197670

Group type: EXPERIMENTAL
Intervention: FiO2 of 0.5 with CPAP (OLV-CPAP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: FiO2 of 1.0 without CPAP (OLV-100)
Number of subjects: 20